# Glipizide Drug Interactions

## Drug Overview
- **Generic Name:** Glipizide
- **Brand Names:** Glucotrol, Glucotrol XL
- **Drug Class:** Sulfonylurea (Second-generation)
- **Primary Use:** Type 2 Diabetes Mellitus
- **Mechanism:** Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors and closing ATP-sensitive potassium channels; also has extrapancreatic effects improving insulin sensitivity
- **FDA Approval:** 1994

---

## Major Drug-Drug Interactions (Severity: HIGH - Avoid or Extreme Caution)

### 1. Bosentan
- **Interacting Drug:** Bosentan (Tracleer)
- **Interaction Type:** Metabolic interaction
- **Mechanism:** Bosentan induces CYP enzymes, potentially reducing glipizide levels
- **Clinical Effect:** Loss of glycemic control; severe liver injury risk
- **Management:** Avoid combination if possible; close monitoring required
- **Source:** Drugs.com Drug Interactions Database

### 2. Miconazole (Oral/Systemic)
- **Interacting Drug:** Miconazole (oral form)
- **Interaction Type:** Potent CYP2C9 inhibition
- **Mechanism:** Miconazole inhibits glipizide metabolism
- **Clinical Effect:** Severe, prolonged hypoglycemia
- **Management:** Monitor closely; consider alternative antifungal
- **Source:** FDA Prescribing Information (Glucotrol XL); Drugs.com

### 3. Fluconazole
- **Interacting Drug:** Fluconazole (Diflucan)
- **Interaction Type:** CYP2C9 inhibition
- **Mechanism:** Fluconazole increases glipizide plasma concentrations by ~57%
- **Clinical Effect:** Significant hypoglycemia risk
- **Management:** Monitor blood glucose closely; may need glipizide dose reduction
- **Source:** FDA Prescribing Information (Glucotrol XL); Clinical pharmacology study data

---

## Moderate Drug-Drug Interactions (Severity: MODERATE - Use with Caution)

### Drugs That POTENTIATE Hypoglycemia (Increase Glipizide Effect)

#### Other Antidiabetic Agents
- **Interacting Drugs:** 
  - Insulin (all types)
  - Metformin
  - SGLT2 Inhibitors: Empagliflozin (Jardiance), Dapagliflozin (Farxiga)
  - GLP-1 Agonists: Semaglutide (Ozempic), Dulaglutide (Trulicity)
  - DPP-4 Inhibitors: Sitagliptin (Januvia)
  - Pioglitazone (Actos)
- **Interaction Type:** Additive glucose-lowering effect
- **Clinical Effect:** Increased hypoglycemia risk
- **Management:** May need to reduce glipizide dose; monitor glucose closely
- **Source:** FDA Prescribing Information; Drugs.com

#### NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- **Interacting Drugs:** Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam, Indomethacin, Ketorolac, Piroxicam
- **Interaction Type:** Protein binding displacement; possible CYP inhibition
- **Mechanism:** NSAIDs are highly protein-bound and may displace glipizide
- **Clinical Effect:** Enhanced hypoglycemic effect
- **Management:** Monitor blood glucose; may need glipizide dose adjustment
- **Source:** FDA Prescribing Information; NCBI Bookshelf (StatPearls)

#### Salicylates
- **Interacting Drugs:** Aspirin (especially high-dose), Salsalate
- **Interaction Type:** Protein binding displacement; intrinsic glucose-lowering
- **Mechanism:** Displaces glipizide from plasma proteins; salicylates have hypoglycemic properties
- **Clinical Effect:** Enhanced hypoglycemia
- **Management:** Monitor glucose; use low-dose aspirin with caution
- **Source:** FDA Prescribing Information; Drugs.com

#### Azole Antifungals
- **Interacting Drugs:** Ketoconazole, Itraconazole, Voriconazole, Posaconazole
- **Interaction Type:** CYP2C9 inhibition
- **Mechanism:** Inhibit metabolism of glipizide
- **Clinical Effect:** Increased glipizide levels; hypoglycemia
- **Management:** Monitor closely; consider dose reduction
- **Source:** FDA Prescribing Information; NCBI Bookshelf

#### Sulfonamide Antibiotics
- **Interacting Drugs:** Sulfamethoxazole, Trimethoprim-Sulfamethoxazole (Bactrim), Sulfasalazine
- **Interaction Type:** Protein binding displacement; CYP inhibition
- **Mechanism:** Displace glipizide from albumin binding sites
- **Clinical Effect:** Enhanced hypoglycemia
- **Management:** Monitor glucose closely during antibiotic therapy
- **Source:** FDA Prescribing Information; Drugs.com

#### Beta-Blockers
- **Interacting Drugs:** Propranolol, Metoprolol, Atenolol, Carvedilol, Bisoprolol
- **Interaction Type:** Masks hypoglycemia symptoms; may prolong hypoglycemia
- **Mechanism:** Block adrenergic symptoms (tachycardia, tremor); impair glycogenolysis
- **Clinical Effect:** Masked hypoglycemia recognition; prolonged episodes
- **Management:** Patient education; more frequent glucose monitoring; prefer cardioselective beta-blockers
- **Source:** FDA Prescribing Information; Drugs.com

#### Quinolone Antibiotics
- **Interacting Drugs:** Ciprofloxacin, Levofloxacin, Moxifloxacin, Ofloxacin
- **Interaction Type:** Variable glucose effects; primarily hypoglycemia with sulfonylureas
- **Mechanism:** Fluoroquinolones affect insulin secretion
- **Clinical Effect:** Hypoglycemia (primarily) or hyperglycemia
- **Management:** Monitor blood glucose closely
- **Source:** FDA Prescribing Information; NCBI Bookshelf

#### Coumarins (Warfarin)
- **Interacting Drug:** Warfarin
- **Interaction Type:** Potential mutual protein displacement
- **Mechanism:** Both highly protein-bound
- **Clinical Effect:** Possible enhanced effects of both drugs
- **Management:** Monitor INR and glucose
- **Source:** FDA Prescribing Information; Drugs.com

#### Chloramphenicol
- **Interacting Drug:** Chloramphenicol
- **Interaction Type:** Inhibits glipizide metabolism
- **Mechanism:** CYP2C9 inhibition
- **Clinical Effect:** Enhanced hypoglycemia
- **Management:** Monitor closely; rare use in modern practice
- **Source:** FDA Prescribing Information; Drugs.com

#### Probenecid
- **Interacting Drug:** Probenecid
- **Interaction Type:** Reduces renal excretion
- **Mechanism:** Competes for renal tubular secretion
- **Clinical Effect:** Increased glipizide levels; hypoglycemia
- **Management:** Monitor blood glucose
- **Source:** FDA Prescribing Information

#### MAO Inhibitors
- **Interacting Drugs:** Phenelzine, Tranylcypromine, Selegiline
- **Interaction Type:** Enhanced hypoglycemic effect
- **Mechanism:** May increase insulin release and sensitivity
- **Clinical Effect:** Hypoglycemia
- **Management:** Close monitoring required
- **Source:** FDA Prescribing Information; Drugs.com

#### ACE Inhibitors
- **Interacting Drugs:** Lisinopril, Enalapril, Ramipril, Captopril
- **Interaction Type:** May enhance insulin sensitivity
- **Clinical Effect:** Possible hypoglycemia
- **Management:** Monitor glucose levels
- **Source:** Drugs.com Drug Interactions Database

### Drugs That DECREASE Glipizide Efficacy (May Cause Hyperglycemia)

#### Thiazide Diuretics
- **Interacting Drugs:** Hydrochlorothiazide, Chlorthalidone, Indapamide
- **Interaction Type:** Pharmacodynamic antagonism
- **Mechanism:** Thiazides can cause hyperglycemia and hypokalemia (reducing insulin secretion)
- **Clinical Effect:** Loss of glycemic control
- **Management:** Monitor blood glucose; may need glipizide dose increase
- **Source:** FDA Prescribing Information; Drugs.com

#### Loop Diuretics
- **Interacting Drugs:** Furosemide (Lasix), Bumetanide, Torsemide
- **Interaction Type:** May cause hyperglycemia
- **Clinical Effect:** Worsened glycemic control
- **Management:** Monitor blood glucose
- **Source:** Drugs.com Drug Interactions Database

#### Corticosteroids
- **Interacting Drugs:** Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone
- **Interaction Type:** Pharmacodynamic antagonism
- **Mechanism:** Increase gluconeogenesis; cause insulin resistance
- **Clinical Effect:** Significant hyperglycemia
- **Management:** May need substantial glipizide dose increase or additional therapy
- **Source:** FDA Prescribing Information; Drugs.com

#### Thyroid Products
- **Interacting Drugs:** Levothyroxine (Synthroid), Liothyronine
- **Interaction Type:** Pharmacodynamic antagonism
- **Mechanism:** Thyroid hormones increase glucose absorption and hepatic glucose output
- **Clinical Effect:** May worsen glycemic control
- **Management:** Monitor glucose when adjusting thyroid therapy
- **Source:** FDA Prescribing Information; Drugs.com

#### Phenothiazines
- **Interacting Drugs:** Chlorpromazine, Prochlorperazine, Promethazine
- **Interaction Type:** Hyperglycemic effect
- **Mechanism:** May cause insulin resistance; affect glucose metabolism
- **Clinical Effect:** Worsened glycemic control
- **Management:** Monitor blood glucose
- **Source:** FDA Prescribing Information

#### Estrogens and Oral Contraceptives
- **Interacting Drugs:** Ethinyl estradiol, Combined oral contraceptives, Conjugated estrogens
- **Interaction Type:** May impair glucose tolerance
- **Clinical Effect:** Possible loss of glycemic control
- **Management:** Monitor blood glucose
- **Source:** FDA Prescribing Information; Drugs.com

#### Phenytoin
- **Interacting Drug:** Phenytoin (Dilantin)
- **Interaction Type:** Inhibits insulin secretion
- **Mechanism:** Direct effect on pancreatic beta cells
- **Clinical Effect:** Hyperglycemia
- **Management:** Monitor glucose closely
- **Source:** FDA Prescribing Information

#### Nicotinic Acid (Niacin)
- **Interacting Drug:** Niacin
- **Interaction Type:** Impairs glucose tolerance
- **Mechanism:** Affects insulin sensitivity
- **Clinical Effect:** Hyperglycemia
- **Management:** Monitor glucose; may need dose adjustment
- **Source:** FDA Prescribing Information

#### Sympathomimetics
- **Interacting Drugs:** Pseudoephedrine, Phenylephrine, Epinephrine, Albuterol
- **Interaction Type:** Counter-regulatory effect
- **Mechanism:** Stimulate glycogenolysis and gluconeogenesis
- **Clinical Effect:** Hyperglycemia
- **Management:** Monitor blood glucose with prolonged use
- **Source:** FDA Prescribing Information; Drugs.com

#### Calcium Channel Blockers
- **Interacting Drugs:** Nifedipine, Verapamil, Diltiazem, Amlodipine
- **Interaction Type:** Variable effects; may impair insulin secretion
- **Clinical Effect:** Possible hyperglycemia
- **Management:** Monitor glucose
- **Source:** FDA Prescribing Information

#### Isoniazid
- **Interacting Drug:** Isoniazid
- **Interaction Type:** Hyperglycemic effect
- **Mechanism:** May impair glucose tolerance
- **Clinical Effect:** Worsened glycemic control
- **Management:** Monitor blood glucose during TB treatment
- **Source:** FDA Prescribing Information

### Drugs That Affect Glipizide Absorption

#### Colesevelam
- **Interacting Drug:** Colesevelam (Welchol)
- **Interaction Type:** Reduced absorption
- **Mechanism:** Bile acid sequestrant binds glipizide in GI tract
- **Clinical Effect:** Reduced glipizide bioavailability
- **Management:** Administer glipizide at least 4 hours BEFORE colesevelam
- **Source:** FDA Prescribing Information (Glucotrol XL)

#### Other Bile Acid Sequestrants
- **Interacting Drugs:** Cholestyramine, Colestipol
- **Interaction Type:** Reduced absorption (theoretical)
- **Clinical Effect:** May reduce glipizide efficacy
- **Management:** Separate administration by 4 hours
- **Source:** Clinical extrapolation from colesevelam data

---

## Minor Drug-Drug Interactions (Severity: LOW)

### Commonly Co-Prescribed Medications (Unknown Interaction Status)
- **Drugs:** 
  - Acetaminophen (Tylenol)
  - Vitamin B12
  - Vitamin C
  - Vitamin D2/D3
  - Fish Oil/Omega-3
  - CoQ10
  - Atorvastatin (Lipitor)
  - Rosuvastatin (Crestor)
  - Cetirizine (Zyrtec)
  - Pregabalin (Lyrica)
  - Duloxetine (Cymbalta)
  - Apixaban (Eliquis)
  - Clopidogrel (Plavix)
  - Hydrocodone/Acetaminophen (Norco)
- **Source:** Drugs.com (Listed as "Unknown" - no documented interactions)

---

## Drug-Food Interactions

### Alcohol
- **Severity:** Moderate to Major
- **Mechanism:** 
  - Alcohol inhibits hepatic gluconeogenesis
  - May cause disulfiram-like reaction (facial flushing) with some sulfonylureas
- **Clinical Effect:** 
  - Hypoglycemia (especially with reduced food intake)
  - Potential flushing reaction
- **Recommendation:** Avoid excessive alcohol; if drinking, do so with food; avoid if diabetes poorly controlled
- **Source:** FDA Prescribing Information; Drugs.com

### Meals
- **Timing:** Glipizide immediate-release should be taken 30 minutes before meals
- **Extended-Release:** Glucotrol XL should be taken with breakfast
- **Source:** FDA Prescribing Information

---

## Disease Interactions

### 1. Cardiovascular Risk (Major)
- **Warning:** UGDP study showed increased cardiovascular mortality with tolbutamide
- **FDA Position:** Warning extends to all sulfonylureas as a class
- **Management:** Discuss risks vs benefits; monitor for cardiovascular events
- **Source:** FDA Prescribing Information (Glucotrol)

### 2. Diabetic Ketoacidosis (DKA) (Major)
- **Contraindication:** Glipizide is NOT appropriate for DKA
- **Reason:** DKA requires insulin therapy
- **Source:** FDA Prescribing Information

### 3. Renal/Hepatic Disease (Major)
- **Effect:** Reduced drug clearance
- **Risk:** Prolonged hypoglycemia
- **Management:** 
  - Hepatic impairment: Start at 2.5 mg once daily
  - Renal impairment: Consider 50% dose reduction if GFR <50 mL/min
- **Source:** FDA Prescribing Information; RxList

### 4. GI Narrowing (Moderate)
- **Applies to:** Glucotrol XL (extended-release) only
- **Risk:** Obstructive symptoms with non-dissolvable formulation
- **Management:** Avoid Glucotrol XL in patients with severe GI narrowing
- **Source:** FDA Prescribing Information (Glucotrol XL)

### 5. Hypoglycemia Risk (Moderate)
- **High-Risk Conditions:**
  - Elderly patients
  - Malnutrition
  - Adrenal/pituitary insufficiency
  - Irregular eating patterns
  - Strenuous exercise
  - Alcohol use
- **Management:** Lower starting doses; careful monitoring; patient education
- **Source:** FDA Prescribing Information; NCBI Bookshelf

### 6. G6PD Deficiency (Moderate)
- **Risk:** Hemolytic anemia
- **Management:** Consider non-sulfonylurea alternative
- **Source:** FDA Prescribing Information; Drugs.com

### 7. Hyponatremia (Moderate)
- **Risk:** Sulfonylureas may cause SIADH-like syndrome
- **Management:** Monitor sodium levels in at-risk patients
- **Source:** Drugs.com Disease Interactions

---

## Summary Statistics
- **Total Known Drug Interactions:** 499
- **Major Interactions:** 24
- **Moderate Interactions:** 449
- **Minor Interactions:** 26
- **Disease Interactions:** 7
- **Food/Alcohol Interactions:** 1

---

## Clinical Recommendations for Safe Use

1. **Before Starting Glipizide:**
   - Confirm Type 2 diabetes diagnosis (not Type 1, not DKA)
   - Assess renal and hepatic function
   - Review medication list for interactions
   - Screen for G6PD deficiency in appropriate populations
   - Counsel on hypoglycemia risk

2. **Dosing Considerations:**
   - Start low (2.5-5 mg daily), especially in elderly
   - Immediate-release: 30 minutes before meals
   - Extended-release: With breakfast
   - Maximum: 20 mg/day for IR; 20 mg/day for XL

3. **Monitoring:**
   - Regular blood glucose monitoring
   - Periodic HbA1c
   - Watch for hypoglycemia symptoms
   - Monitor when starting/stopping interacting medications

4. **Patient Education:**
   - Recognize and treat hypoglycemia
   - Carry glucose tablets
   - Timing of doses with meals
   - Avoid excessive alcohol
   - Inform all providers about glipizide use
   - Watch for hypoglycemia with beta-blockers

5. **Drug Interaction Management:**
   - Separate glipizide from colesevelam by 4 hours
   - Monitor closely with azole antifungals
   - May need dose adjustment with corticosteroid therapy
   - Extra caution with NSAIDs and aspirin

---

## References
1. FDA Prescribing Information - Glucotrol (Glipizide) Tablets
2. FDA Prescribing Information - Glucotrol XL (Glipizide Extended-Release)
3. Drugs.com Drug Interactions Database (https://www.drugs.com/drug-interactions/glipizide.html)
4. NCBI Bookshelf - Glipizide StatPearls (November 2025)
5. DrugBank - Glipizide Monograph
6. Mayo Clinic - Glipizide Drug Information
7. MedlinePlus - Glipizide Information
8. RxList - Glipizide/Glucotrol Drug Information
